The Problem

No Approved
Therapies

Multiple Failures

Multiple failures due to lack of efficacy and/or adverse events

Market Focus

Market focus is on F2-F4 patients.

• No drug development emphasis on F1 or decompensated liver patients.
  
• The patients don’t “feel” sick, making compliance an issue
  
• No drug candidates for decompensated liver disease
  

NASH

NASH is highly complex disease that can cause a severely compromised lifestyle and even death – a targeted and multi-pronged approach is required for success.